哌拉西林/他唑巴坦治疗卒中相关性肺炎的疗效研究  

Clinical Effect Research of Piperacillin/tazobactam in the Treatment of Patients with Stroke Associated Pneumonia

作　　者：孙海华[1] 肖佩荣[1] 赵新国[2] 

机构地区：[1]东南大学医学院附属盐城医院神经内科,江苏省盐城市224001 [2]东南大学医学院附属盐城医院呼吸内科,江苏省盐城市224001

出　　处：《实用心脑肺血管病杂志》2013年第1期24-26,共3页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

摘　　要：目的观察哌拉西林/他唑巴坦对卒中相关性肺炎的治疗效果。方法将64例卒中相关性肺炎患者随机分为治疗组和对照组,各32例。治疗组给予哌拉西林/他唑巴坦2.5g,1次/8h,静脉滴注;对照组给予阿奇霉素0.5g,1次/d,静脉滴注,连用5d后改为口服,同时给予头孢曲松3.0g,1次/d,静脉滴注。两组疗程均为14d,以临床疗效及细菌学评价作为观察指标,收集相关数据,进行统计学分析。结果治疗组和对照组临床治疗有效率分别为93.8%和81.3%,治疗组和对照组细菌总清除率分别为93.3%和71.4%,两组上述疗效比较,差异均有统计学意义(P<0.05)。治疗组和对照组不良反应发生率分别为3.1%和9.4%。结论哌拉西林/他唑巴坦治疗卒中相关性肺炎有效,且不良反应少,值得在临床推广。Objective To explore the effectiveness of piperacillin/tazobactam for stroke-associated pneumonia（SAP）.Methods 64 patients with stroke associated pneumonia were randomized into treatment group and control group.Treatment group was administered intravenously with piperacillin/tazobactam（2.5g） every 8h for 14 days.Control group was administered intravenously with azithromycin（0.5g/day） for 5 days,and then instead of oral medication.While ceftriaxone injection（3.0g/day） was administered intravenously.The total course of treatment was 14 days,the data of bacteriology and clinical efficacy were collected and analyzed.Results The treatment group and the control group in clinical treatment efficiency were 93.8% and 81.3%,the treatment group and the control group the total bacterial clearance rates were 93.3% and 71.4%,two groups of the comparison of curative effect,the differences were statistically significant（P0.05）.The incidence of adverse reactions in treatment group and the control group were respectively 3.1% and 9.4%.Conclusion Piperacillin/tazobactam can be considered as effective drug for stroke-associated pneumonia.

关 键 词：卒中 肺炎 哌拉西林 他唑巴坦 治疗结果 

分 类 号：R743.3[医药卫生—神经病学与精神病学]